{
    "hands_on_practices": [
        {
            "introduction": "Effective management of pediatric heart failure begins with a precise hemodynamic assessment. This practice challenges you to apply the hemodynamic equivalent of Ohm's law, a fundamental principle of cardiovascular physiology, to quantify the afterload imposed on the right ventricle. By translating raw data from a cardiac catheterization into the clinically vital metric of Pulmonary Vascular Resistance ($PVR$), you will develop the crucial skill of connecting diagnostic numbers to their profound physiological implications for patient care .",
            "id": "5184748",
            "problem": "A $5$-year-old, $15$-$\\mathrm{kg}$ child with advanced heart failure undergoes right heart catheterization for hemodynamic assessment. The measured mean pulmonary artery pressure (mPAP) is $45$ $\\mathrm{mmHg}$, the pulmonary capillary wedge pressure (PCWP), a surrogate for downstream left atrial pressure, is $10$ $\\mathrm{mmHg}$, and the cardiac output (CO), measured by the Fick principle, is $3.0$ $\\mathrm{L/min}$. Starting from the hemodynamic analog of Ohm’s law that relates the pressure gradient $\\Delta P$, the flow $Q$, and the resistance $R$ across a vascular circuit, and using the definitions of mean pulmonary artery pressure, pulmonary capillary wedge pressure, and cardiac output, derive the expression needed to compute the pulmonary vascular resistance (PVR). Then compute the child’s PVR. Express the final result in Wood units, where Wood units are $\\mathrm{mmHg} \\cdot \\mathrm{min}/\\mathrm{L}$. Round your answer to three significant figures. Finally, based on your computed value, briefly interpret whether the right ventricle (RV) is experiencing markedly increased workload due to afterload.",
            "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, and objective.\n\n**Step 1: Extract Givens**\n- Patient age: $5$ years\n- Patient weight: $15$ kg\n- Condition: Advanced heart failure\n- Measurement: Mean pulmonary artery pressure (mPAP) = $45$ $\\mathrm{mmHg}$\n- Measurement: Pulmonary capillary wedge pressure (PCWP) = $10$ $\\mathrm{mmHg}$\n- Measurement: Cardiac output (CO) = $3.0$ $\\mathrm{L/min}$\n- Governing Principle: Hemodynamic analog of Ohm’s law, $\\Delta P = Q \\times R$, relating pressure gradient ($\\Delta P$), flow ($Q$), and resistance ($R$).\n- Required output 1: Derive the expression for pulmonary vascular resistance (PVR).\n- Required output 2: Compute PVR in Wood units ($\\mathrm{mmHg} \\cdot \\mathrm{min}/\\mathrm{L}$).\n- Required output 3: Round the numerical answer to three significant figures.\n- Required output 4: Interpret the result regarding right ventricular (RV) workload.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically sound, as it is based on fundamental, established principles of cardiovascular physiology. The hemodynamic analog of Ohm's law, $\\Delta P = Q \\times R$, is the standard model for describing pressure-flow relationships in vascular circuits. The parameters provided—mPAP, PCWP, and CO—are the correct and necessary inputs for calculating PVR. The values themselves ($45$ $\\mathrm{mmHg}$, $10$ $\\mathrm{mmHg}$, $3.0$ $\\mathrm{L/min}$) are clinically plausible for a child with advanced heart failure and secondary pulmonary hypertension. The problem is self-contained, well-posed, and stated in objective, unambiguous language. It does not violate any scientific principles, is not based on false premises, and is directly relevant to the field of pediatric cardiology. No invalidating flaws are present.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A complete solution will be provided.\n\n**Derivation and Calculation**\n\nThe problem requires the derivation and calculation of pulmonary vascular resistance (PVR) using the hemodynamic analog of Ohm's law. This law states that the pressure drop ($\\Delta P$) across a vascular bed is equal to the flow ($Q$) through it multiplied by its resistance ($R$).\n$$\n\\Delta P = Q \\times R\n$$\nTo apply this principle to the pulmonary circulation, we must identify the correct parameters for $\\Delta P$, $Q$, and $R$.\n\n1.  **Pressure Gradient ($\\Delta P$)**: The pressure gradient across the pulmonary vasculature is the difference between the pressure entering the circuit and the pressure exiting it. The pressure entering the pulmonary arteries from the right ventricle is the mean pulmonary artery pressure (mPAP). The pressure at the exit of the pulmonary circuit, in the pulmonary veins draining into the left atrium, is the mean left atrial pressure. The pulmonary capillary wedge pressure (PCWP) is a clinically measured surrogate for the mean left atrial pressure. Therefore, the transpulmonary pressure gradient is:\n    $$\n    \\Delta P = \\text{mPAP} - \\text{PCWP}\n    $$\n\n2.  **Flow ($Q$)**: Under normal steady-state conditions, the flow through the pulmonary circulation is equal to the systemic circulation's flow. This flow is the cardiac output (CO).\n    $$\n    Q = \\text{CO}\n    $$\n\n3.  **Resistance ($R$)**: The resistance of the pulmonary vascular bed is the pulmonary vascular resistance (PVR).\n    $$\n    R = \\text{PVR}\n    $$\n\nSubstituting these specific terms into the general Ohm's law analog provides the governing equation for the pulmonary circuit:\n$$\n(\\text{mPAP} - \\text{PCWP}) = \\text{CO} \\times \\text{PVR}\n$$\nTo derive the expression needed to compute PVR, we rearrange this equation by dividing both sides by the cardiac output (CO):\n$$\n\\text{PVR} = \\frac{\\text{mPAP} - \\text{PCWP}}{\\text{CO}}\n$$\nThis is the required expression.\n\nNow, we compute the child's PVR using the given values:\n- mPAP = $45$ $\\mathrm{mmHg}$\n- PCWP = $10$ $\\mathrm{mmHg}$\n- CO = $3.0$ $\\mathrm{L/min}$\n\nSubstituting these values into the derived expression:\n$$\n\\text{PVR} = \\frac{45 \\, \\mathrm{mmHg} - 10 \\, \\mathrm{mmHg}}{3.0 \\, \\mathrm{L/min}}\n$$\n$$\n\\text{PVR} = \\frac{35 \\, \\mathrm{mmHg}}{3.0 \\, \\mathrm{L/min}}\n$$\n$$\n\\text{PVR} \\approx 11.666... \\, \\frac{\\mathrm{mmHg} \\cdot \\mathrm{min}}{\\mathrm{L}}\n$$\nThe problem specifies that the final result should be expressed in Wood units, where $1$ Wood unit is defined as $1$ $\\mathrm{mmHg} \\cdot \\mathrm{min}/\\mathrm{L}$. Therefore, the PVR is approximately $11.666...$ Wood units.\n\nRounding the answer to three significant figures, we get:\n$$\n\\text{PVR} = 11.7 \\text{ Wood units}\n$$\n\n**Interpretation of the Result**\n\nThe right ventricle (RV) pumps blood into the pulmonary artery, and the PVR represents the afterload, or resistance, that the RV must overcome to eject blood. A normal PVR in a child is typically less than $3$ Wood units. A value between $3$ and $6$ Wood units is considered mildly to moderately elevated, while a value greater than $6$ Wood units is considered severely elevated. The calculated PVR for this child is $11.7$ Wood units, which is markedly and critically elevated. This high afterload places a severe and unsustainable pressure-volume workload on the right ventricle, leading to RV hypertrophy, dilation, and eventual failure, which is a hallmark of disease progression in this clinical context. Therefore, the right ventricle is experiencing a markedly increased workload due to the severe elevation in afterload.",
            "answer": "$$\n\\boxed{11.7}\n$$"
        },
        {
            "introduction": "Once hemodynamic status is assessed, a cornerstone of managing acute decompensated heart failure is reducing preload through diuresis. This exercise moves from assessment to intervention, focusing on the use of a potent loop diuretic, furosemide. More than a simple dose calculation, this practice hones your ability to design a proactive monitoring schedule based on the drug's pharmacokinetics and pharmacodynamics, ensuring both efficacy and patient safety .",
            "id": "5184734",
            "problem": "A $7$-$\\text{kg}$ infant with acute decompensated pediatric heart failure is admitted to the pediatric intensive care unit and requires loop diuretic therapy to reduce preload while closely preserving renal perfusion and electrolyte homeostasis. A first dose of intravenous (IV) furosemide is ordered at a weight-based dose of $1$ $\\text{mg}/\\text{kg}$ given as an IV bolus. Using fundamental pediatric pharmacology principles of weight-based dosing, calculate the IV furosemide dose in milligrams to administer. In addition, design and justify a $6$-hour monitoring schedule for urine output (UOP), serum electrolytes (sodium, potassium, chloride, bicarbonate), and serum creatinine that is appropriate for an infant receiving an initial loop diuretic bolus for heart failure.\n\nYour final numeric answer should be the calculated IV furosemide dose expressed in milligrams. Round your dose to three significant figures and state the dose in $\\text{mg}$.",
            "solution": "The problem statement is deemed valid. It is scientifically grounded, well-posed, and objective. It consists of two components: first, a quantitative calculation of a medication dose based on provided parameters, and second, the design of a physiologically-justified clinical monitoring plan. Both components are solvable using fundamental principles of pharmacology and physiology.\n\nThe first task is to calculate the total dose of intravenous (IV) furosemide for the infant. Let $m$ be the mass of the infant and $D_{\\text{specific}}$ be the prescribed weight-based dose. The total dose, $D_{\\text{total}}$, is the product of these two quantities.\n\nGiven:\nInfant mass, $m = 7$ $\\text{kg}$\nPrescribed dose, $D_{\\text{specific}} = 1$ $\\text{mg}/\\text{kg}$\n\nThe total dose is calculated as:\n$$D_{\\text{total}} = m \\times D_{\\text{specific}}$$\nSubstituting the given values into the equation:\n$$D_{\\text{total}} = 7 \\text{ kg} \\times 1 \\frac{\\text{mg}}{\\text{kg}} = 7 \\text{ mg}$$\nThe problem requires the answer to be expressed with three significant figures. The initial calculation yields the integer $7$. To represent this value with three significant figures, we write it as $7.00$. Therefore, the total dose to be administered is $7.00$ $\\text{mg}$.\n\nThe second task is to design and justify a $6$-hour monitoring schedule for urine output (UOP), serum electrolytes (sodium, potassium, chloride, bicarbonate), and serum creatinine. The design of this schedule is dictated by the pharmacokinetic and pharmacodynamic properties of IV furosemide, a potent loop diuretic. The fundamental pharmacological principles of IV furosemide are critical here. Its mechanism of action involves the inhibition of the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, which leads to a profound increase in the renal excretion of sodium, potassium, chloride, and water. The pharmacokinetics of IV administration are characterized by a rapid onset of action, typically within $5$ minutes; a peak effect at approximately $30$ minutes; and a duration of action of approximately $2$ to $4$ hours. This duration can be prolonged in patients with cardiac or renal impairment. Based on these principles, a monitoring schedule must be structured to capture the diuretic response and promptly detect potential adverse effects such as volume depletion and electrolyte imbalances.\n\nA proposed $6$-hour monitoring schedule is as follows.\n\nFirst, monitoring of urine output (UOP) is the primary indicator of the drug's efficacy. UOP should be measured hourly for the entire $6$-hour period. In a pediatric intensive care unit (PICU) setting, this measurement is accurately facilitated by an indwelling urinary catheter. The justification for this frequency is that hourly monitoring allows for real-time assessment of the diuretic response. The onset of diuresis should be observed within the first hour, and the peak response is expected within the first $1$ to $2$ hours. A target UOP is generally considered to be greater than $1$ $\\text{mL} \\cdot \\text{kg}^{-1} \\cdot \\text{hr}^{-1}$. Observing the UOP trend over $6$ hours helps determine the duration of action and assesses whether the diuretic effect is adequate, excessive, or absent, thereby guiding subsequent therapy.\n\nSecond, serum electrolytes (sodium, potassium, chloride, bicarbonate) must be monitored to detect adverse effects resulting from the drug's mechanism of action. A baseline measurement must be taken immediately before the administration of the first dose. A follow-up measurement should be performed at the end of the initial observation period, that is, at $6$ hours post-dose. If diuresis is exceptionally brisk (e.g., $> 4$ $\\text{mL} \\cdot \\text{kg}^{-1} \\cdot \\text{hr}^{-1}$) or if the baseline potassium is in the low-normal range, an earlier check at $2$ to $4$ hours may be warranted. The justification is that furosemide causes renal wasting of sodium, potassium, and chloride. This can lead to hyponatremia, hypochloremia, and most critically, hypokalemia, which can precipitate cardiac arrhythmias. The loss of chloride in excess of sodium and potassium can also induce a hypochloremic metabolic alkalosis, reflected by an increase in serum bicarbonate. A $6$-hour interval allows sufficient time for significant diuresis to occur and for these shifts to be reflected in serum concentrations, enabling timely correction.\n\nThird, serum creatinine, a marker of renal function, must be monitored. A baseline measurement is essential before starting therapy. A follow-up check should be performed at $6$ hours post-dose, concurrent with the electrolyte measurement. The justification is that heart failure itself can compromise renal perfusion, and aggressive diuresis can lead to volume depletion, causing a pre-renal acute kidney injury which manifests as an increase in serum creatinine. While changes in creatinine may lag, a $6$-hour measurement in a critically ill infant provides an early data point to establish the trajectory of renal function in response to the intervention. A significant increase would signal the need to reassess volume status and potentially adjust the diuretic strategy.\n\nIn summary, the specific monitoring protocol is structured around these time points:\n- **Time $t=0$:** Obtain a baseline blood sample for serum electrolytes and creatinine. Administer the $7.00$ $\\text{mg}$ IV furosemide bolus. Record the initial state of the urinary drainage system.\n- **Time $t=1$ hr:** Record UOP for the first hour.\n- **Time $t=2$ hr:** Record UOP for the second hour.\n- **Time $t=3$ hr:** Record UOP for the third hour.\n- **Time $t=4$ hr:** Record UOP for the fourth hour.\n- **Time $t=5$ hr:** Record UOP for the fifth hour.\n- **Time $t=6$ hr:** Record UOP for the sixth hour. Obtain a follow-up blood sample for serum electrolytes and creatinine. Assess the total $6$-hour UOP and the overall fluid balance.",
            "answer": "$$\n\\boxed{7.00}\n$$"
        },
        {
            "introduction": "Beyond managing fluid balance, improving cardiac function often requires targeted inotropic support, especially in cases of systolic dysfunction. This problem delves into the precise dosing of digoxin, a cardiac glycoside with a narrow therapeutic index. Applying first-principles pharmacokinetics, you will calculate both loading and maintenance doses, a process that underscores the critical importance of quantitative reasoning and clinical vigilance in administering high-risk medications .",
            "id": "5184708",
            "problem": "An $8$-month-old infant with decompensated systolic heart failure due to a large ventricular septal defect weighs $10\\,\\mathrm{kg}$ and has normal renal function with no interacting medications. You plan to initiate oral digoxin using an elixir formulation. Assume the following pharmacokinetic parameters, consistent with infants with normal renal function and no interacting drugs: oral bioavailability $F = 0.80$, target steady-state plasma concentration $C_{\\text{target}} = 0.80\\,\\mu\\mathrm{g}/\\mathrm{L}$ (equivalently $0.80\\,\\mathrm{ng}/\\mathrm{mL}$) for heart failure, apparent volume of distribution $V_{d} = 10\\,\\mathrm{L}/\\mathrm{kg}$, and weight-normalized systemic clearance $\\mathrm{CL} = 3.5\\,\\mathrm{mL}/\\mathrm{min}/\\mathrm{kg}$. Assume a one-compartment model with instantaneous distribution relative to absorption and first-order elimination, and linear pharmacokinetics over the concentration range of interest.\n\nUsing only first-principles mass balance and pharmacokinetic definitions, determine:\n- the total oral loading dose required to achieve $C_{\\text{target}}$; and\n- a once-daily total oral maintenance dose that will maintain $C_{\\text{target}}$ at steady state.\n\nAdditionally, in your reasoning, explicitly outline the expected clinical signs of digoxin toxicity in infants and first-line management protocols, including when to consider antidotal therapy.\n\nFor grading, report only the total oral loading dose as a single number. Express the final loading dose in micrograms and round your answer to three significant figures. Do not include units in your final reported answer.",
            "solution": "The problem is assessed to be valid as it is scientifically grounded in established pharmacokinetic principles, well-posed with sufficient and consistent data, and objectively stated. It is a standard, formalizable problem in clinical pharmacology relevant to the specified topic of pediatric heart failure management.\n\nThis problem requires the calculation of an oral loading dose and a daily oral maintenance dose of digoxin for an infant, based on a one-compartment pharmacokinetic model. The guiding principles are mass balance and the definitions of fundamental pharmacokinetic parameters.\n\nFirst, we calculate the patient's total apparent volume of distribution ($V_{d, \\text{total}}$) and total systemic clearance ($\\mathrm{CL}_{\\text{total}}$) by scaling the given weight-normalized parameters by the patient's weight ($W$).\nGiven:\nPatient weight, $W = 10\\,\\mathrm{kg}$\nWeight-normalized apparent volume of distribution, $V_d = 10\\,\\mathrm{L}/\\mathrm{kg}$\nWeight-normalized systemic clearance, $\\mathrm{CL} = 3.5\\,\\mathrm{mL}/\\mathrm{min}/\\mathrm{kg}$\n\nThe total parameters are:\n$V_{d, \\text{total}} = V_d \\times W = (10\\,\\mathrm{L}/\\mathrm{kg}) \\times (10\\,\\mathrm{kg}) = 100\\,\\mathrm{L}$\n$\\mathrm{CL}_{\\text{total}} = \\mathrm{CL} \\times W = (3.5\\,\\mathrm{mL}/\\mathrm{min}/\\mathrm{kg}) \\times (10\\,\\mathrm{kg}) = 35\\,\\mathrm{mL}/\\mathrm{min}$\n\n**1. Calculation of the Total Oral Loading Dose ($D_L$)**\n\nThe purpose of a loading dose is to rapidly achieve a target plasma concentration ($C_{\\text{target}}$) by filling the apparent volume of distribution. The amount of drug required in the body to achieve this concentration is the product of the total volume of distribution and the target concentration.\n\nAmount of drug in body = $V_{d, \\text{total}} \\times C_{\\text{target}}$\n\nGiven:\nTarget plasma concentration, $C_{\\text{target}} = 0.80\\,\\mu\\mathrm{g}/\\mathrm{L}$\nTotal volume of distribution, $V_{d, \\text{total}} = 100\\,\\mathrm{L}$\n\nAmount of drug in body = $(100\\,\\mathrm{L}) \\times (0.80\\,\\mu\\mathrm{g}/\\mathrm{L}) = 80\\,\\mu\\mathrm{g}$\n\nThis is the amount of drug that must be present systemically (in the bloodstream and tissues). Since the drug is administered orally, we must account for its oral bioavailability ($F$), which is the fraction of the administered dose that reaches systemic circulation. The required oral loading dose ($D_{L, \\text{oral}}$) is therefore:\n\n$D_{L, \\text{oral}} = \\frac{\\text{Amount of drug in body}}{F}$\n\nGiven:\nOral bioavailability, $F = 0.80$\n\n$D_{L, \\text{oral}} = \\frac{80\\,\\mu\\mathrm{g}}{0.80} = 100\\,\\mu\\mathrm{g}$\n\nThe problem requires the answer to be rounded to three significant figures. The calculated value is exactly $100$.\n\n**2. Calculation of the Total Oral Maintenance Dose ($D_M$)**\n\nAt steady state, the rate of drug administration must equal the rate of drug elimination to maintain a constant average plasma concentration. This is a direct application of mass balance.\n\nRate of Dosing = Rate of Elimination\n\nThe rate of elimination is the product of the total systemic clearance and the steady-state plasma concentration ($C_{ss}$), which is our target concentration, $C_{\\text{target}}$.\n\nRate of Elimination = $\\mathrm{CL}_{\\text{total}} \\times C_{\\text{target}}$\n\nThe rate of dosing for an oral regimen is the bioavailable fraction of the maintenance dose ($D_M$) divided by the dosing interval ($\\tau$).\n\nRate of Dosing = $\\frac{D_{M, \\text{oral}} \\times F}{\\tau}$\n\nEquating these two rates:\n$\\frac{D_{M, \\text{oral}} \\times F}{\\tau} = \\mathrm{CL}_{\\text{total}} \\times C_{\\text{target}}$\n\nSolving for the once-daily oral maintenance dose ($D_{M, \\text{oral}}$), where $\\tau = 1\\,\\text{day}$:\n$D_{M, \\text{oral}} = \\frac{\\mathrm{CL}_{\\text{total}} \\times C_{\\text{target}} \\times \\tau}{F}$\n\nWe must ensure consistent units. We will convert $\\mathrm{CL}_{\\text{total}}$ from $\\mathrm{mL}/\\mathrm{min}$ to $\\mathrm{L}/\\mathrm{day}$:\n$\\mathrm{CL}_{\\text{total}} = 35\\,\\frac{\\mathrm{mL}}{\\mathrm{min}} \\times \\frac{1\\,\\mathrm{L}}{1000\\,\\mathrm{mL}} \\times \\frac{60\\,\\mathrm{min}}{1\\,\\mathrm{hr}} \\times \\frac{24\\,\\mathrm{hr}}{1\\,\\mathrm{day}} = 50.4\\,\\mathrm{L}/\\mathrm{day}$\n\nNow, we can calculate the dose:\n$D_{M, \\text{oral}} = \\frac{(50.4\\,\\mathrm{L}/\\mathrm{day}) \\times (0.80\\,\\mu\\mathrm{g}/\\mathrm{L}) \\times (1\\,\\mathrm{day})}{0.80}$\n$D_{M, \\text{oral}} = \\frac{40.32\\,\\mu\\mathrm{g}}{0.80} = 50.4\\,\\mu\\mathrm{g}$\n\nThe required once-daily total oral maintenance dose is $50.4\\,\\mu\\mathrm{g}$.\n\n**3. Clinical Signs of Digoxin Toxicity and Management Protocols**\n\nThe problem additionally requests an outline of the clinical aspects of digoxin toxicity.\n\n**Expected Clinical Signs of Digoxin Toxicity in Infants:**\n-   **Cardiac Manifestations:** Bradycardia is the most common and often earliest sign of toxicity in infants. Other arrhythmias are frequent and may include varying degrees of atrioventricular (AV) block (first, second, or third-degree), sinoatrial block, junctional or atrial tachycardia with block, and ventricular arrhythmias such as premature ventricular contractions (PVCs), bigeminy, or trigeminy.\n-   **Gastrointestinal Manifestations:** Vomiting, nausea, anorexia, and feeding intolerance are common but non-specific early symptoms.\n-   **Neurologic Manifestations:** In infants, these may present as non-specific signs such as drowsiness, lethargy, or irritability. The classic visual disturbances (e.g., chromatopsia, blurred vision) described in adults are not reportable by pre-verbal infants.\n-   **Metabolic Disturbances:** In acute toxicity, hyperkalemia is a serious and ominous finding, resulting from the inhibition of the $\\text{Na}^+/\\text{K}^+$-ATPase pump. Conversely, pre-existing electrolyte abnormalities such as hypokalemia, hypomagnesemia, and hypercalcemia can potentiate digoxin's toxic effects by increasing its binding to the $\\text{Na}^+/\\text{K}^+$-ATPase.\n\n**First-Line Management Protocols:**\n-   **Immediate Discontinuation:** The first step is to stop further administration of digoxin.\n-   **Monitoring:** Continuous electrocardiogram (ECG) monitoring is crucial to detect and characterize arrhythmias. Serum electrolytes (especially potassium), magnesium, calcium, and renal function must be monitored frequently. Serum digoxin concentration should be measured, although the clinical picture, not the level alone, guides management, particularly in chronic toxicity.\n-   **Supportive Care:**\n    -   Electrolyte correction: Gently correct hypokalemia or hypomagnesemia, as this can reduce the risk of arrhythmias. Correction of hypokalemia must be done with extreme caution in the presence of AV block.\n    -   Arrhythmia management: Symptomatic bradycardia or high-degree AV block unresponsive to atropine may require temporary cardiac pacing. Ventricular tachyarrhythmias are typically managed with lidocaine or phenytoin, although antidotal therapy is preferred if available and indicated.\n\n**Consideration for Antidotal Therapy (Digoxin-Specific Antibody Fragments):**\nAntidotal therapy with digoxin-specific antibody fragments (e.g., Digibind®, DigiFab®) is the definitive treatment for severe toxicity and is indicated in the following situations:\n-   Presence of life-threatening cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, progressive high-degree heart block, or symptomatic bradycardia unresponsive to standard therapies).\n-   Acute ingestion of a massive dose (e.g., >0.1 mg/kg in a child).\n-   Acute toxicity associated with severe hyperkalemia (e.g., serum $\\text{K}^+$ > $5.5\\,\\mathrm{mEq}/\\mathrm{L}$).\n-   Evidence of end-organ dysfunction (e.g., cardiogenic shock, renal failure) resulting from digoxin-induced cardiac compromise.",
            "answer": "$$\\boxed{100}$$"
        }
    ]
}